Biocon Q2FY23 net profit slips 10% to Rs 168 Cr; Revenue up 26%

IOL Chemicals and Pharmaceuticals Q2FY23 net profit drops to Rs 15.6 Cr

The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA

Lynparza in combination with Abiraterone and prednisone receives positive opinion from EU CHMP

First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations

GL Chemtech appoints Dr. John Warner as Green Chemistry Innovation Advisor

Reinforcing GLC’s commitment to sustainable processing in pharmaceutical chemistry

Suven Life Sciences posts Q2FY23 consolidated loss at Rs. 23.18 Cr

The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022

Supriya Lifescience Q2 FY2023 profit slips to Rs. 16.86 Cr

The company has reported total income of Rs. 114.77 crores during the period ended September 30, 2022.

Biocon Biologics features on ASIA IP ELITE List 2022

This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list

GSK India announces 9% sales growth across General Medicines and Specialty business

The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth

Alembic receives USFDA final approval for Cyclophosphamide Capsules

Cyclophosphamide Capsules, 25 mg and 50 mg, have an estimated market size of US$ 8 million for twelve months ending Sep 2022 according to IQVIA.

Stelis receives recommendation from EMA granting market authorization for Kauliv

Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.